An integrated computational workflow for efficient and quantitative modeling of renin inhibitors.
暂无分享,去创建一个
[1] Ajay N. Jain,et al. Molecular Shape and Medicinal Chemistry: A Perspective , 2010, Journal of medicinal chemistry.
[2] R. Sedrani,et al. Direct renin inhibitors as a new therapy for hypertension. , 2010, Journal of medicinal chemistry.
[3] M. Grütter,et al. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. , 1991, Journal of structural biology.
[4] John P. Overington,et al. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. , 2010, Drug discovery today.
[5] Serdar Durdagi,et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. , 2010, Journal of molecular graphics & modelling.
[6] L. Prade,et al. Piperidine-based renin inhibitors: upper chain optimization. , 2010, Bioorganic & medicinal chemistry letters.
[7] R. Cramer,et al. Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.
[8] N. Powell,et al. Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[9] N. Powell,et al. Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[10] Richard D. Cramer,et al. Rethinking 3D-QSAR , 2010, J. Comput. Aided Mol. Des..
[11] Christoph A. Sotriffer,et al. Virtual screening : principles, challenges, and practical guidelines , 2011 .
[12] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[13] Nicolas Foloppe,et al. Drug-like Bioactive Structures and Conformational Coverage with the LigPrep/ConfGen Suite: Comparison to Programs MOE and Catalyst , 2010, J. Chem. Inf. Model..
[14] L. Prade,et al. Design and optimization of new piperidines as renin inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[15] Wei Zhao,et al. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines. , 2009, Bioorganic & medicinal chemistry letters.
[16] David E. Shaw,et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..
[17] C. Bayly,et al. Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension. , 2010, Bioorganic & medicinal chemistry letters.
[18] C. Oefner,et al. Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site. , 1999, Bioorganic & medicinal chemistry letters.
[19] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[20] Jonas Boström,et al. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. , 2003, Journal of molecular graphics & modelling.
[21] L. Prade,et al. New classes of potent and bioavailable human renin inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[22] Wei Zhao,et al. Optimization of orally bioavailable alkyl amine renin inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[23] J. A. Grant,et al. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..
[24] L. Prade,et al. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. , 2009, Journal of medicinal chemistry.
[25] M. Kansy,et al. Piperidine-renin inhibitors compounds with improved physicochemical properties. , 1999, Bioorganic & medicinal chemistry letters.
[26] Jitender Verma,et al. 3D-QSAR in drug design--a review. , 2010, Current topics in medicinal chemistry.
[27] Ajay N. Jain,et al. Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.
[28] Hans Matter,et al. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. , 2011, Bioorganic & medicinal chemistry letters.
[29] N. Powell,et al. Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. , 2007, Bioorganic & medicinal chemistry.
[30] B. Musafia,et al. Biasing conformational ensembles towards bioactive-like conformers for ligand-based drug design , 2010, Expert opinion on drug discovery.
[31] J. Falgueyret,et al. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines. , 2011, Bioorganic & medicinal chemistry letters.
[32] Benjamin A. Ellingson,et al. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..
[33] Hans Matter,et al. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[34] Ketopiperazine-based renin inhibitors: optimization of the "C" ring. , 2006, Bioorganic & medicinal chemistry letters.
[35] J. Falgueyret,et al. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines. , 2011, Bioorganic & medicinal chemistry letters.